← Back to Clinical Trials
Recruiting NCT04613388

NCT04613388 Registry Study of Proton Radiotherapy in Lymphoma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04613388
Status Recruiting
Phase
Sponsor University Hospital Heidelberg
Condition Mediastinal Lymphoma
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2018-08-01
Primary Completion 2030-08-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Assesment of Effectiveness and side effects

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2018-08-01 with a primary completion date of 2030-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim is to record and document a mediastinal PT and the corresponding follow-up data (effectiveness and side effects). General recommendations for planning and feasibility are made within the framework of this study.

Eligibility Criteria

Inclusion Criteria: Histologically confirmed lymphoma according to WHO * Patient consent * Patient age ≥18 years. * Presence of the need for mediastinal radiotherapy and the presumed benefit of mediastinal radiotherapy using protons in comparison to photon radiation (e.g. improved heart, lungs, and breast protection compared to photon radiation). * Ability of the patient to give consent Exclusion Criteria: Age \<18 years * Non-consent of the patient to the disclosure of his data * Cancellation of the patient's participation in the study

Contact & Investigator

Central Contact

Laila König, MD

✉ laila.könig@med.uni-heidelberg.de

📞 +49 6221

Principal Investigator

Laila König, MD

PRINCIPAL INVESTIGATOR

University Hospital Heidelberg

Frequently Asked Questions

Who can join the NCT04613388 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Mediastinal Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04613388 currently recruiting?

Yes, NCT04613388 is actively recruiting participants. Contact the research team at laila.könig@med.uni-heidelberg.de for enrollment information.

Where is the NCT04613388 trial being conducted?

This trial is being conducted at Heidelberg, Germany.

Who is sponsoring the NCT04613388 clinical trial?

NCT04613388 is sponsored by University Hospital Heidelberg. The principal investigator is Laila König, MD at University Hospital Heidelberg. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology